Research
Hormonal
Perioperative use of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) may increase the risk of bronchoaspiration.
Clinicians should be cautious about the use of GLP-1-RAs in the perioperative setting due to the risk of bronchoaspiration.
ModerateSupportsmedium confidence
recent case reports and retrospective observational studies, while anecdotal, suggest that the perioperative use of GLP-1-RAs may increase the risk of bronchoaspiration.
Why this rating
Based on anecdotal evidence from case reports and observational studies.
Source
Perioperative management of patients on glucagon-like peptide-1 receptor agonists
Glenio B. Mizubuti et al. · Current Opinion in Anaesthesiology · 2024
DOI 10.1097/aco.0000000000001348
reviewCited 27×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →